These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 23334341)

  • 1. An open, prospective, randomized study comparing the immunogenicity and safety of two inactivated hepatitis A pediatric vaccines in toddlers, children and adolescents in China.
    Li RC; Li Y; Yi N; Huang L; Wan Z; Zhang Y; Rasuli A
    Pediatr Infect Dis J; 2013 Feb; 32(2):e77-81. PubMed ID: 23334341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity, safety, and interchangeability of two inactivated hepatitis A vaccines in Chilean children.
    Abarca K; Ibánez I; Perret C; Vial P; Zinsou JA
    Int J Infect Dis; 2008 May; 12(3):270-7. PubMed ID: 17988917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interchangeability and tolerability of two inactivated hepatitis A vaccines in Chinese children.
    Zhang ZL; Zhu XJ; Wang X; Liang M; Sun J; Liu Y; Gao ZG; Wu JY; Dong XJ; Liu RK; Chen JT; Zhang YQ; Wang W; Zhang LP; Yin W
    Vaccine; 2012 Jun; 30(27):4028-33. PubMed ID: 22537990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity and reactogenicity of Avaxim (160 AU) as compared with Havrix (1440 EL.U) as a booster following primary immunization with Havrix (1440 EL.U) against hepatitis A.
    Zuckerman JN; Kirkpatrick CT; Huang M
    J Travel Med; 1998 Mar; 5(1):18-22. PubMed ID: 9772311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and safety of an inactivated hepatitis A vaccine in Taiwanese adults and children.
    Lee CY; Huang LM; Lee PI; Chiu HH; Dumas R; Milcamps B; Lin W
    Southeast Asian J Trop Med Public Health; 2000 Mar; 31(1):29-36. PubMed ID: 11023061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparing live attenuated and inactivated hepatitis A vaccines: an immunogenicity study after one single dose.
    Zheng H; Chen Y; Wang F; Gong X; Wu Z; Miao N; Zhang X; Li H; Chen C; Hou X; Cui F; Wang H
    Vaccine; 2011 Nov; 29(48):9098-103. PubMed ID: 21875638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of two doses of an inactivated hepatitis a vaccine given 6 months apart in healthy toddlers, children, and adolescents aged 12 months to 15 years in China: a phase IV study.
    Shi N; Rasuli A; Thollot Y
    Hum Vaccin Immunother; 2019; 15(3):748-754. PubMed ID: 30403910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term immunity after two doses of inactivated hepatitis A vaccine, in Argentinean children.
    López EL; Contrini MM; Mistchenko A; Debbag R
    Pediatr Infect Dis J; 2010 Jun; 29(6):568-70. PubMed ID: 20195189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the safety and immunogenicity of live attenuated and inactivated hepatitis A vaccine in healthy Chinese children aged 18 months to 16 years: results from a randomized, parallel controlled, phase IV study.
    Ma F; Yang J; Kang G; Sun Q; Lu P; Zhao Y; Wang Z; Luo J; Wang Z
    Clin Microbiol Infect; 2016 Sep; 22(9):811.e9-811.e15. PubMed ID: 27345175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concomitant administration of a virosome-adjuvanted hepatitis a vaccine with routine childhood vaccines at age twelve to fifteen months: a randomized controlled trial.
    Dagan R; Amir J; Livni G; Greenberg D; Abu-Abed J; Guy L; Ashkenazi S; Foresner G; Tewald F; Schätzl HM; Hoffmann D; Ibanez R; Herzog C
    Pediatr Infect Dis J; 2007 Sep; 26(9):787-93. PubMed ID: 17721372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modeling the long-term persistence of hepatitis A antibody after a two-dose vaccination schedule in Argentinean children.
    López EL; Contrini MM; Mistchenko A; Kieffer A; Baggaley RF; Di Tanna GL; Desai K; Rasuli A; Armoni J
    Pediatr Infect Dis J; 2015 Apr; 34(4):417-25. PubMed ID: 25764099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Seven-year follow-up of the immune response after one or 2 doses of inactivated hepatitis A vaccine given at 1 year of age in the Mendoza Province of Argentina.
    Espul C; Benedetti L; Linares M; Cuello H; Lo Castro I; Thollot Y; Rasuli A
    Hum Vaccin Immunother; 2017 Nov; 13(11):2707-2712. PubMed ID: 28933624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized, double-blind study in healthy adults to assess the boosting effect of Vaqta or Havrix after a single dose of Havrix.
    Connor BA; Phair J; Sack D; McEniry D; Hornick R; Banerjee D; Jensen E; Kuter B
    Clin Infect Dis; 2001 Feb; 32(3):396-401. PubMed ID: 11170947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of immunogenicity and persistence between inactivated hepatitis A vaccine Healive® and Havrix® among children: A 5-year follow-up study.
    Yu C; Song Y; Qi Y; Li C; Jiang Z; Li C; Zhang W; Wang L; Xia J
    Hum Vaccin Immunother; 2016 Oct; 12(10):2595-2602. PubMed ID: 27385349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and safety of an inactivated hepatitis A vaccine when coadministered with Diphtheria-tetanus-acellular pertussis and haemophilus influenzae type B vaccines in children 15 months of age.
    Trofa AF; Klein NP; Paul IM; Michaels MG; Goessler M; Chandrasekaran V; Blatter M
    Pediatr Infect Dis J; 2011 Sep; 30(9):e164-9. PubMed ID: 21494175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomised comparison of two inactivated hepatitis A vaccines, Avaxim and Vaqta, given as a booster to subjects primed with Avaxim.
    Clarke P; Kitchin N; Souverbie F
    Vaccine; 2001 Aug; 19(31):4429-33. PubMed ID: 11483268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and tolerability of a paediatric presentation of a virosomal hepatitis A vaccine in Chilean children aged 1-16 years.
    Abarca K; Ibáñez I; de la Fuente P; Cerda L; Bergeret J; Frösner G; Ibarra H
    Vaccine; 2011 Nov; 29(48):8855-62. PubMed ID: 21983354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity of an inactivated hepatitis A pediatric vaccine: three-year post-booster follow-up.
    Dagan R; Greenberg D; Weber F
    Vaccine; 2005 Oct; 23(44):5144-8. PubMed ID: 16043271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and safety of an inactivated hepatitis A vaccine administered concomitantly with diphtheria-tetanus-acellular pertussis and haemophilus influenzae type B vaccines to children less than 2 years of age.
    Nolan T; Bernstein H; Blatter MM; Bromberg K; Guerra F; Kennedy W; Pichichero M; Senders SD; Trofa A; Collard A; Sullivan DC; Descamps D
    Pediatrics; 2006 Sep; 118(3):e602-9. PubMed ID: 16950952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the immunogenicity and safety of 3 inactivated hepatitis A vaccines in Korean children aged 12 to 18 months: An open-label, randomized, prospective, multicenter study.
    Hong SS; Choi UY; Ma SH; Lee SY; Han SB; Kim KH; Kang JH; Kim JH
    Medicine (Baltimore); 2019 Feb; 98(6):e14364. PubMed ID: 30732169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.